Cambrex To Invest $50 M to Expand US-Based API MfgBy
Cambrex has announced plans to invest more than $50 million to expand its mid-scale and large-scale active pharmaceutical ingredient (API) manufacturing capacity at its site in Charles City, Iowa.
The expansion, which will be operational in early 2022, will add three large-scale manufacturing work centers and one mid-scale work center to increase the site’s capacity by 30%. When the expansion is completed, the Charles City site will employ more than 400 people.
The investment will be the company’s sixth major investment at the site in the past eight years, which included prior investments in mid- to large-scale API manufacturing and high-potency manufacturing. Cambrex’s Charles City facility is located on a 45-acre site and is part of the company’s drug-substance business unit, which manufactures APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.